Artigos

Search for articles

BJO Oncology - Placeholder

Prevalence and Management of Immediate Adverse Reactions to Chemotherapy in Breast Cancer Patients: A Retrospective Study

Abstract Objective To analyze the prevalence, characteristics, and management of immediate adverse reactions (ARs) to chemotherapeutic agents in breast cancer patients treated at the National Cancer Institute (Instituto Nacional del Cáncer, INCAN, in Spanish) in Paraguay. Materials and Methods A retrospective, observational, and cross-sectional study was conducted using clinical records...
BJO Oncology - Placeholder

The action of Palbociclib on the Cell Cycle of Head and Neck Squamous Cell Carcinoma: A Systematic Review

Abstract This study evaluates the action of Palbociclib in the cell cycle of HPV-negative head and neck squamous cell carcinoma. Initially approved for HER2- and HR + breast cancer. Palbociclib induces cellular senescence, increases the efficacy of Cetuximab, restores p16 function and decreases phosphorylated Rb, suggesting an improvement in survival in both...
BJO Oncology - Placeholder

Phase-III INTERLACE Trial: A Study Requires Post-Hoc Analysis of Subgroups with Locally-Advanced Cervical Cancer

To the Editor, In recent years, few studies have provided oncological outcomes with the potential to change clinical practice for patients with cervical cancer, leaving the standard model of combined chemoradiotherapy for locally-advanced disease largely unchanged. Over the past year, 2 phase-III clinical trials—KEYNOTE-A181 and INTERLACE2—have introduced new evidence with...
BJO Oncology - Placeholder

Analysis of the Impact of the SARS-CoV-2 Pandemic on the Stage and Access to Oncology Services in Brazil for the Treatment of Rectal Cancer

Abstract Introduction Cancer is a major social, public health, and economic challenge worldwide, accounting for 1 in 6 deaths globally, according to Globocan 2022. Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, there has been a noticeable impact on the provision of services to oncology patients. The present...
BJO Oncology - Placeholder

Infrared Thermography – A Novel Tool in the Surgical Treatment of H3 K27M-Altered Diffuse Midline Spinal Cord Glioma: Technical and Case Report

Abstract Diffuse midline gliomas (DMGs), H3K27-altered, are rare and aggressive tumors primarily affecting children, though adult cases occur. These gliomas present significant surgical challenges, and novel techniques are needed to improve outcomes. We present the case of a 53-year-old male with a solid expansive lesion located at T12 to L1,...
BJO Oncology - Placeholder

Papillary Carcinoma in a Thyroglossal Cyst: A Case Report

Abstract We herein report a case of papillary thyroid carcinoma with an unusual presentation, inside a thyroglossal cyst. An 83-year-old male patient reported a long-standing nodule persisting for over 40 years, with progressive enlargement and periodic dysphonia. The patient underwent total thyroidectomy combined with the Sistrunk procedure. Resection of the...
BJO Oncology - Placeholder

MultiClass Machine Learning-based Identification of Anoikis-related Genes Across Three Adult T-cell Leukemia/Lymphoma Subtypes

Abstract Introduction Adult T-cell leukemia/lymphoma (ATLL) is a type of cancer that originates from T-cells infected with the human T-cell lymphotropic virus type 1 (HTLV-1). Anoikis is a programmed cell death process that occurs when the contact between cells or the extracellular matrix is lost. We aim to identify the...
BJO Oncology - Placeholder

Targeted Therapy in a Rare Spindle Cell Tumor with Gene Fusion Rearrangement: A Case Report ETV6-NTRK3

Abstract Introduction Advances in genomic tools have significantly improved the classification of soft tissue tumors (STTs), enabling the identification of specific subsets characterized by recurrent fusions and genetic alterations involving the Raf-1 proto-oncogene, serine/threonine kinase (RAF1), B-Raf proto-oncogene, serine/threonine kinase (BRAF), and neurotrophic tyrosine receptor kinase (NTRK) genes. The present...
BJO Oncology - Placeholder

Pharmacogenetic Testing for Fluoropyrimidines at Instituto Nacional de Câncer, Brazil

The present letter focuses on the pharmacogenetic (PGx) testing of variants of the dihydropyrimidine dehydrogenase (DPYD) gene available at Instituto Nacional de Câncer (INCA), Rio de Janeiro, for cancer patients who are candidates for treatment with the fluoropyrimidines 5-fluorouracil (5-FU) and/or capecitabine.1 The rationale for DPYD genotyping is as follows:...
BJO Oncology - Placeholder

Suffering-based Medicine in the Age of Artificial Intelligence

Abstract The present paper delves into suffering-based medicine (SBM) and its potential use with artificial intelligence (AI). Suffering-based medicine provides a hermeneutical approach to patient care, allowing a deeper understanding of the subjective experiences and meaning behind a patient's suffering. With the rise of large language models (LLMs) based on...